RxDoctor Payments Data

Selena Ellis, MD

Neurology · Berkeley, CANPI 1265412993

Payments from drug & device makers

$3,332in general payments, 2019–2025

Across 170 payments — averaging $19.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Impel Pharmaceuticals Inc.$383
  • Teva Pharmaceuticals USA, Inc.$221
  • Lilly USA, LLC$178
  • Amgen$148
  • AstraZeneca$146
  • plus $994 from 15 others

What the payments were for

  • Food & beverage$3,319100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,332 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$255,638
Medicare patients
281
Services billed
11,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate88$139,636
UbrelvyUbrogepant27$51,999
Emgality PenGalcanezumab-Gnlm21$38,192
Aimovig AutoinjectorErenumab-Aooe29$37,570
Ajovy AutoinjectorFremanezumab-Vfrm15$18,936
Sumatriptan Succinate77$16,854
Sumatriptan22$6,068
Gabapentin179$4,702
RizatriptanRizatriptan Benzoate73$1,992
Duloxetine Hcl64$1,682
Nortriptyline Hcl61$1,327
Levetiracetam18$1,194
Pregabalin27$850
Prazosin Hcl15$798
Zonisamide41$623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$145$139,63688 claims
AbbVieUbrelvy$1,262$51,99927 claims
Upsher-smith Laboratories LLCTopiramate$123$14411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,996 neurology providers in California.

Other neurology in Berkeley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →